NASDAQ:YMAB

Y-mAbs Therapeutics (YMAB) Stock Forecast, Price & News

$8.24

+0.07 (+0.86%)

(As of 06/5/2023 ET)

Compare

Today's Range: $7.92
▼
$8.42
50-Day Range: $3.03
▼
$10.34
52-Week Range: $2.70
▼
$20.48

Volume: 212,059 shs
Average Volume: 572,758 shs
Market Capitalization: $359.92 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $13.67

Y-mAbs Therapeutics MarketRank™ Forecast

Analyst Rating: Hold
2.25 Rating Score
Upside/Downside: 65.9% Upside
$13.67 Price Target
Short Interest: Healthy
5.46% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.26
Based on 3 Articles This Week
Insider Trading: Acquiring Shares
$981,791 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.94) to ($0.56) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.30 out of 5 stars

Medical Sector

246th out of 985 stocks

Pharmaceutical Preparations Industry

113th out of 486 stocks

3.1

Analyst's Opinion

Consensus Rating
Y-mAbs Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 5 buy ratings, 5 hold ratings, and 2 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $13.67, Y-mAbs Therapeutics has a forecasted upside of 65.9% from its current price of $8.24.
Amount of Analyst Coverage
Y-mAbs Therapeutics has only been the subject of 4 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
5.46% of the float of Y-mAbs Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Y-mAbs Therapeutics has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Y-mAbs Therapeutics has recently decreased by 2.70%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Y-mAbs Therapeutics does not currently pay a dividend.
Dividend Growth
Y-mAbs Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for YMAB.

2.9

News and Social Media Coverage

News Sentiment
Y-mAbs Therapeutics has a news sentiment score of 1.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Y-mAbs Therapeutics this week, compared to 4 articles on an average week.
Search Interest
17 people have searched for YMAB on MarketBeat in the last 30 days. This is an increase of 467% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Y-mAbs Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $981,791.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
21.50% of the stock of Y-mAbs Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
53.96% of the stock of Y-mAbs Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Y-mAbs Therapeutics are expected to grow in the coming year, from ($0.94) to ($0.56) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Y-mAbs Therapeutics is -4.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Y-mAbs Therapeutics is -4.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Y-mAbs Therapeutics has a P/B Ratio of 3.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Y-mAbs Therapeutics (NASDAQ:YMAB) Stock

Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.

Receive YMAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Y-mAbs Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

YMAB Stock News Headlines

June 2, 2023 | finance.yahoo.com

Y-mAbs Therapeutics (NASDAQ:YMAB investor three-year losses grow to 81% as the stock sheds US$53m this past week

May 26, 2023 | finance.yahoo.com

Y-mAbs Announces Presentation of GD2-SADA Study at ASCO

June 5, 2023 | Legacy Research (Affiliate) (Ad)

“Amazon Loophole” could hand you $28,544 in “royalty” payouts

Thanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.

May 26, 2023 | finance.yahoo.com

Y-mAbs Announces Presentation of Naxitamab Data at ASCO

May 24, 2023 | americanbankingnews.com

Brokerages Set Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Target Price at $13.13

May 23, 2023 | finance.yahoo.com

Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma approved in Brazil

May 15, 2023 | msn.com

B of A Securities Maintains Y-Mabs Therapeutics (YMAB) Neutral Recommendation

May 15, 2023 | markets.businessinsider.com

B of A Securities Maintains Neutral Rating for Y-mAbs Therapeutics: Here's What You Need To Know

June 5, 2023 | Legacy Research (Affiliate) (Ad)

The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty

A unique type of investment could help you make more money than you will need for the rest of your life. It’s what we call the “Amazon secret royalty program.” It’s an income stream that allows you to collect $1,000s… $10,000s… or more every year! Learn how to collect your first payout before June 13th.

May 15, 2023 | markets.businessinsider.com

Bank of America Securities Keeps Their Hold Rating on Y-Mabs Therapeutics (YMAB)

May 15, 2023 | americanbankingnews.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Increased to $12.00 by Analysts at Bank of America

May 14, 2023 | americanbankingnews.com

Q2 2023 Earnings Forecast for Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Issued By Wedbush

May 13, 2023 | finance.yahoo.com

New Forecasts: Here's What Analysts Think The Future Holds For Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

May 13, 2023 | americanbankingnews.com

FY2027 Earnings Forecast for Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Issued By Wedbush

May 13, 2023 | americanbankingnews.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Rating Upgraded by Wedbush

May 12, 2023 | msn.com

Wedbush Upgrades Y-Mabs Therapeutics (YMAB)

May 12, 2023 | msn.com

Morgan Stanley Maintains Y-Mabs Therapeutics (YMAB) Underweight Recommendation

May 11, 2023 | americanbankingnews.com

Novartis (NYSE:NVS) & Y-mAbs Therapeutics (NASDAQ:YMAB) Financial Review

May 10, 2023 | msn.com

Y-mAbs gains as Wedbush upgrades after Q1 results

May 10, 2023 | markets.businessinsider.com

Analyst Upgrades Y-mAbs On Bullish Danyelza Sales Outlook, Improved Visibility

May 10, 2023 | finance.yahoo.com

Y-mAbs Therapeutics First Quarter 2023 Earnings: Beats Expectations

May 10, 2023 | finance.yahoo.com

Q1 2023 Y-mAbs Therapeutics Inc Earnings Call

May 9, 2023 | finanznachrichten.de

Y-mAbs Therapeutics, Inc: Y-mAbs Reports First Quarter 2023 Financial Results and Recent Corporate Developments and Updates 2023 Financial Guidance

May 8, 2023 | finance.yahoo.com

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates

May 8, 2023 | finance.yahoo.com

Y-mAbs Reports First Quarter 2023 Financial Results and Recent Corporate Developments and Updates 2023 Financial Guidance

May 7, 2023 | americanbankingnews.com

Y-mAbs Therapeutics (YMAB) Scheduled to Post Quarterly Earnings on Monday

May 5, 2023 | msn.com

Preview: Y-mAbs Therapeutics's Earnings

See More Headlines

YMAB Price History

30 days | 90 days | 365 days | Advanced Chart

YMAB Company Calendar

Last Earnings: 5/08/2023
Today: 6/05/2023
Next Earnings (Estimated): 8/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:YMAB
CUSIP: N/A
CIK: 1722964
Web: www.ymabs.com
Phone: (646) 885-8505
Fax: N/A
Employees: 148
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $13.67
High Stock Price Forecast: $27.00
Low Stock Price Forecast: $4.00
Forecasted Upside/Downside: +66.3%
Consensus Rating: Hold
Rating Score (0-4): 2.25
Research Coverage: 12 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.69)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-95,570,000.00
Net Margins: -98.48%
Pretax Margin: -98.48%
Return on Equity: -64.77%
Return on Assets: -50.27%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.78
Quick Ratio: 4.44

Sales & Book Value

Annual Sales: $65.27 million
Price / Sales: 5.50
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.50 per share
Price / Book: 3.29

Miscellaneous

Outstanding Shares: 43,680,000
Free Float: 34,287,000
Market Cap: $359.05 million
Optionable: Not Optionable
Beta: 0.77

Key Executives

Thomas Gad
President, Chief Executive Officer & Director

Joris Wiel Jan Wilms
Chief Operating Officer & Senior Vice President

Bo Kruse
CFO, Secretary. Treasurer & Executive VP

Torben Lund-Hansen
Chief Technology Officer & Senior Vice President

Steen Lisby
Chief Scientific Officer & Senior Vice President

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

YMAB Stock - Frequently Asked Questions

Should I buy or sell Y-mAbs Therapeutics stock right now?: 12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Y-mAbs Therapeutics in the last twelve months. There are currently 2 sell ratings, 5 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" YMAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in YMAB, but not buy additional shares or sell existing shares.
View YMAB analyst ratings or view top-rated stocks.
What is Y-mAbs Therapeutics' stock price forecast for 2023?: 12 brokers have issued 12-month price objectives for Y-mAbs Therapeutics' shares. Their YMAB share price forecasts range from $4.00 to $27.00. On average, they predict the company's stock price to reach $13.67 in the next twelve months. This suggests a possible upside of 66.3% from the stock's current price.
View analysts price targets for YMAB or view top-rated stocks among Wall Street analysts.
How have YMAB shares performed in 2023?: Y-mAbs Therapeutics' stock was trading at $4.88 at the beginning of 2023. Since then, YMAB stock has increased by 68.4% and is now trading at $8.22.
View the best growth stocks for 2023 here.
When is Y-mAbs Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our YMAB earnings forecast.
How were Y-mAbs Therapeutics' earnings last quarter?: Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) issued its quarterly earnings results on Monday, May, 8th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.16. The business earned $20.30 million during the quarter, compared to the consensus estimate of $15.55 million. Y-mAbs Therapeutics had a negative net margin of 98.48% and a negative trailing twelve-month return on equity of 64.77%. The firm's revenue for the quarter was up 93.3% compared to the same quarter last year. During the same quarter last year, the company posted ($0.64) earnings per share.
What other stocks do shareholders of Y-mAbs Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Y-mAbs Therapeutics investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Corbus Pharmaceuticals (CRBP), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Occidental Petroleum (OXY), VBI Vaccines (VBIV), Vaxart (VXRT) and Amarin (AMRN).

When did Y-mAbs Therapeutics IPO?: (YMAB) raised $80 million in an IPO on Friday, September 21st 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity served as the underwriters for the IPO and BTIG was co-manager.
What is Y-mAbs Therapeutics' stock symbol?: Y-mAbs Therapeutics trades on the NASDAQ under the ticker symbol "YMAB."
Who are Y-mAbs Therapeutics' major shareholders?: Y-mAbs Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.41%), State Street Corp (1.75%), Geode Capital Management LLC (1.52%), AIGH Capital Management LLC (0.98%), Acadian Asset Management LLC (0.91%) and Charles Schwab Investment Management Inc. (0.54%). Insiders that own company stock include Biotech Aps Wg, Bo Kruse, David N Gill, Johan Wedell-Wedellsborg, Pedro Claus Juan Moller-San, Thomas Gad and Vignesh Rajah.
View institutional ownership trends.
How do I buy shares of Y-mAbs Therapeutics?: Shares of YMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Y-mAbs Therapeutics' stock price today?: One share of YMAB stock can currently be purchased for approximately $8.22.
How much money does Y-mAbs Therapeutics make?: Y-mAbs Therapeutics (NASDAQ:YMAB) has a market capitalization of $359.05 million and generates $65.27 million in revenue each year. The company earns $-95,570,000.00 in net income (profit) each year or ($1.69) on an earnings per share basis.
How many employees does Y-mAbs Therapeutics have?: The company employs 148 workers across the globe.
How can I contact Y-mAbs Therapeutics?: Y-mAbs Therapeutics' mailing address is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. The official website for the company is www.ymabs.com. The company can be reached via phone at (646) 885-8505 or via email at info@ymabs.com.

This page (NASDAQ:YMAB) was last updated on 6/5/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial